Sofra™
Developed from a breakthrough discovery in innate immunology, the Sofra technology platform represents a revolutionary approach to drug design by translating a new understanding of innate biology into targeted therapeutics that enable precision control of disease-relevant signalling.
Sofra is based on the use of synthetic nucleic acids, known as oligonucleotides, to mimic natural regulators of the body’s defence system.
This novel approach enables selective and modular tuning of immune sensors, reducing or stimulating their associated biological responses to mitigate a broad range of diseases and enhance RNA-based therapies and emerging therapeutic technologies.
Sofra is focused on inflammatory and autoimmune diseases such as rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology for cancer treatment.
The global autoimmune disease therapeutics market was worth US$163.2 billion in 2024 and is expected to reach US$219.6 billion by 2035, while the worldwide immuno-oncology market was US$43 billion in 2023 and is projected to hit US$284 billion by 2033.
Sofra’s most advanced clinical asset, SOF-SKN™, is a topical treatment that targets an inflammatory sensor called Toll-like receptor 7 (TLR7). The drug has the potential to change the treatment paradigm of the skin disease caused by cutaneous lupus erythematosus (CLE) from merely controlling symptoms to actually treating the disease itself right at the source.
Key areas of focus for the Sofra platform are:
